The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness: A Biomarker Study.

Trial Profile

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness: A Biomarker Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 11 Sep 2017 Status changed from recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 03 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top